Teva’s Ajovy hits endpoint in Chinese Phase III trial for migraine prevention

Teva Pharmaceuticals has unveiled positive data from a Phase III study evaluating Ajovy (fremanezumab) for the prevention of migraines in Chinese adult patients.

Teva’s Ajovy is already approved to prevent migraines in adults in the US and Europe, receiving regulatory approval from the US Food and Drug Administration and the European Medicines Agency in 2018 and 2019 respectively.